Research Collaboration and Exclusive License Agreement - Additional Information (Detail)	12 Months Ended
	Dec. 31, 2021 USD ($) Target	Dec. 31, 2020 USD ($)
Research And Development Arrangement Contract To Perform For Others [Line Items]
Deferred revenue		$ 8,000,000.0
Deferred revenue current	$ 5,163,000	1,950,000
Accounts receivable outstanding	$ 0	8,000,000
Merck Agreement
Research And Development Arrangement Contract To Perform For Others [Line Items]
Collaborative arrangement effective date	Dec. 15, 2020
Number of collaboration targets | Target	2
Non-refundable and non-creditable upfront fee	$ 8,000,000.0
Payable upon selection of second collaboration target	8,000,000.0
Milestone payments	285,000.0
Transaction price	11,400,000
Reimbursable research program funding for first collaboration target	3,400,000
Variable consideration payable upon selection of second collaboration target	8,000,000.0
Aggregate transaction price allocated to unsatisfied performance obligation	7,700,000
Revenue recognized	3,600,000	0
Deferred revenue	5,900,000	8,000,000.0
Deferred revenue current	5,200,000	$ 2,000,000.0
Merck Agreement | Maximum
Research And Development Arrangement Contract To Perform For Others [Line Items]
Milestone payments per collaboration target	142,500,000
Milestone payments upon successful completion of certain commercial milestones	$ 350,000,000.0